Abstract
Abstract
The World Health Organization has a goal of universal drug susceptibility testing for patients with tuberculosis; however, molecular diagnostics to date have focused largely on first-line drugs and predicting binary susceptibilities. We used a multivariable linear mixed model alongside whole genome sequencing and a quantitative microtiter plate assay to relate genomic mutations to minimum inhibitory concentration in 15,211 Mycobacterium tuberculosis patient isolates from 23 countries across five continents. This identified 492 unique MIC-elevating variants across thirteen drugs, as well as 91 mutations likely linked to hypersensitivity. Our results advance genetics-based diagnostics for tuberculosis and serve as a curated training/testing dataset for development of drug resistance prediction algorithms.
Publisher
Research Square Platform LLC
Reference64 articles.
1. WHO. Global Tuberculosis Report 2020. (2020).
2. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: A systematic review and meta-analysis;Schnippel K;J. Antimicrob. Chemother.,2017
3. André, E. et al. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin. Microbiol. Infect. 23, 267.e5-267.e7 (2017).
4. Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?;Cox H;Lancet Infect. Dis.,2018
5. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: A prospective study;Pankhurst LJ;Lancet Respir. Med.,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献